83P Analysis of predictive factors in non-small cell lung cancer patients treated with nivolumab
ConclusionNLR, ALI and LIPI score have the potential to be predictive factors of ICI response in NSCLC patients.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureA. Tamiya: Research grant / Funding (self): Taiho; Research grant / Funding (self): pfizer; Research grant / Funding (self): AstraZeneca; Research grant / Funding (self): Ono pharmaceutical; Research grant / Funding (self): Bristol-Myers Squibb; Research grant / Funding (self): Chugai pharmaceutical; Research grant / Funding (self): Eli Lilly; Research grant / Funding (self): Boehringer Ingelheim; Research grant / Fund...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
31P Development of a biomarker-based calculator to predict the probability to achieve a pathologic complete response after neoadjuvant pembrolizumab in muscle-invasive bladder cancer
ConclusionWe presented the first biomarker-based risk stratification tool that can be used to recommend use of neoadjuvant pembrolizumab in those patients who have equal or greater chances to achieve a pT0 status compared to the literature on neoadjuvant chemotherapy or to RC alone, depending on cisplatin eligibility.Clinical trial identificationPURE01 study (NCT02736266).Legal entity responsible for the studyThe authors.FundingMerck& Co., Inc., Kenilworth, NJ, USA; Associazione Italiana per la Ricerca sul Cancro (AIRC).DisclosureR. Madison: Shareholder / Stockholder / Stock options, Full / Part-time employment, employ...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
172P miR-486-5p counteracts the shedding of MICA/B and CD155 immune-ligands in TNBC patients
ConclusionmiR-486-5p is an immunomodulatory tumor suppressor miRNA acts by alleviating the immunesuppressive profile of TNBC cells.Legal entity responsible for the studyGerman University in Cairo.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
67P Real-world outcomes for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with nivolumab
ConclusionThis real-world study of nivolumab in R/M SCCHN patients in the United States shows that the improved survival demonstrated by nivolumab in CheckMate 141 translates into similar real-world outcomes for patients, with an even greater benefit in first-line patients. These results are consistent with other observational analyses in Europe and reinforce the survival benefit of nivolumab in R/M SCCHN patients as early as first line.Legal entity responsible for the studyBristol-Myers Squibb.FundingBristol-Myers Squibb.DisclosureP. Singh: Full / Part-time employment: Bristol-Myers Squibb. M. You: Full / Part-time employ...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
153P Immune-microbial crosstalk in oral epithelium: A potential role in oral carcinogenesis?
ConclusionDysregulated production of hBD-2 could enhance a proinflammatory vicious circle in OLP, which can further damage healthy neighbouring cells and may over time promote carcinogenesis. Histamine and H4R can modulate hBD-2 response in oral epithelium and may serve as promising targets for therapeutic interventions.Legal entity responsible for the studyTULES Research Group.FundingDoctoral Program in Oral Sciences, University of Helsinki.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
126TiP A phase I study of NBTXR3 activated by radiotherapy for patients with advanced cancers treated with an anti-PD-1 therapy
AbstractBackgroundThe majority of cancer patients are resistant to immune therapy; only around 15% respond to immune checkpoint inhibitors (ICI). Thus, strategies able to increase ICI response are of great interest. Recent work suggests radiotherapy (RT) can act as an immunomodulator to increase the proportion of ICI responders and improve clinical outcomes. However, RT dose and ultimate efficacy are limited by toxicity related to exposure of healthy tissues. NBTXR3 is a first-in-class radioenhancer administered by intratumoral injection, designed at the nanoscale to increase RT energy dose deposition within the tumor. The...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
142P Association of MUC16 mutation with survival of immune checkpoint inhibitor in patients with cancer
ConclusionWe demonstrated that MUC16 mutation can predict survival benefit from ICI therapy in cancer, and suggested that MUC16 mutation should be integrated into predictive biomarker panels for ICI therapy and be validated in future prospective clinical trials.Legal entity responsible for the studyHerui Yao.FundingGrants from the National Natural Science Foundation of China (81372819, 81572596, U1601223), the Natural Science Foundation of Guangdong Province (2017A030313828), the Guangzhou Science and Technology Program (201704020131), the Sun Yat-Sen University Clinical Research 5010 Program (2018007).DisclosureAll author...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
15P Immune escape in acute myeloid leukemia
ConclusionThe majority of AML patients display at least one marker of immune escape at diagnosis. These include decreased HLA class I expression, reduced antigen processing, increased PDL1 expression, secretion of Tim3 by leukemia blasts, or increased Treg counts. The mechanisms of immune suppression in AML are likely heterogenous, similarly to the disease itself. Both PD-L1 and Tim-3 might have prognostic value in selected AML subgroups.Legal entity responsible for the studyThe authors.FundingMinistry of Health of the Czech Republic (Grant no 16-30268A).DisclosureAll authors have declared no conflicts of interest. (Source...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
84P Survival outcomes in stage IV small-cell lung cancer (IV-SCLC): Analysis from SEER database
ConclusionThis real world data analysis reflects that the chance of having long term survivors in SCLC is very low and that mOS has not been improved over the last years. The introduction of new therapies such as immune checkpoints opens a new opportunity for long term survival and better outcomes in this aggressive disease.Legal entity responsible for the studyRoche Farma S.A.FundingRoche Farma S.A.DisclosureJ. de Castro Carpe ño: Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
32P A comprehensive tumour immunogenomics platform for precision immunotherapy: Enabling simultaneous characterization of tumours and the TME from a single FFPE sample
ConclusionWe have developed a novel tumour immunogenomics platform that simultaneously profiles the tumour and TME from a single sample.Legal entity responsible for the studyPersonalis, Inc.FundingPersonalis, Inc.DisclosureR. Power: Shareholder / Stockholder / Stock options, Full / Part-time employment: Personalis, Inc. G. Bartha: Shareholder / Stockholder / Stock options, Full / Part-time employment: Personalis, Inc. J. Harris: Shareholder / Stockholder / Stock options, Full / Part-time employment: Personalis, Inc. S.M. Boyle: Shareholder / Stockholder / Stock options, Full / Part-time employment: Personalis, Inc. E. Levy...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
173TiP PECan study, imaging PD-L1 in cancer: A tool for measuring response to immunotherapy?
This study is now open to recruitment with reporting expected late 2020.Clinical trial identificationUK IRAS ID 256684.Legal entity responsible for the studyKing's College London and Guy's and St Thomas' NHS Foundation Trust.FundingDepartment of Cancer Imaging, King's College London, UK with funding from NanoMab Technology Limited, China.DisclosureG. Chand: Advisory / Consultancy, Shareholder / Stockholder / Stock options: NanoMab Technology Limited. H.H. Ting: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment, Officer / Board of Directors: NanoMab Technology Limited. G. Cook: Research...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
107P Increasing responses to T-cell therapies in solid tumours by the use of an engineered adenovirus coding for TNFa and IL-2
ConclusionThe use of TILT-123 to enable T-cell therapies (including checkpoint-inhibiting antibodies) delivered encouraging preclinical results pointing to it as a valuable approach to increase the number of patients that benefit from T-cell therapies. Those results include not only cell based therapies but also checkpoint inhibitors, a kind of therapy that is making the difference in the field and becoming first-line treatment for an increasing number of indications. Because of the favourable preclinical studies, the first in human clinical trials with TILT-123 will start in the upcoming months.Legal entity responsible fo...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
42P GMP-compliant human monocyte-derived dendritic cells for cancer vaccination generated by using the Quantum ® hollow fiber bioreactor system
ConclusionWe have adapted the Quantum ® system to process one complete apheresis product to yield a large number of mature and functional GMP-compliant monocyte-derived DCs for the use in cancer immunotherapy without any need for fibronectin coating or trypsin digestions.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
68P Dynamic changes in neutrophil-to-lymphocyte ratio of head and neck cancer patients receiving nivolumab in a real-world setting
ConclusionBaseline and 12-wk NLR may allow to distinguish between long and short-term survivors. Improved response rates and survival in our series may be explained by the lower rate of platinum-refractory disease and the use of nivolumab in the first-line setting as well as beyond progression in a substantial proportion of patients. Treatment was well tolerated. These results merit confirmation in a larger sample.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureS. Cabezas-Camarero: Speaker Bureau / Expert testimony: Bristol-Myers Squibb; Advisory / Consultancy: Bristol-Myers ...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
154P ER stress of cancer cell SCC25 induces LOX-1-expressed immunosuppressive neutrophils
ConclusionER stress induction of SCC25 could enhance both LOX-1 expression and immunosuppressive activities of neutrophils.Legal entity responsible for the studyThe authors.FundingMinistry of Science and Technology, Taiwan.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
